# Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Canonical URL: https://biopharmsignal.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-third-quarter-2025-financial-results
Ticker: PLRX
Company: Pliant Therapeutics
Source: Pliant Therapeutics
Published: 2025-11-06 21:05 EST
Original Source URL: https://ir.pliantrx.com
## Summary

Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused

## Article Body
Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused
## Recent Company News
- 2026-05-21 21:30 EST — [Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting) — Source: Pliant Therapeutics
- 2026-05-11 20:05 EST — [Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-first-quarter-2026-financial-results) — Source: Pliant Therapeutics
- 2026-05-06 12:30 EST — [Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-to-participate-in-the-rbc-capital-markets-global-healthcare-conference) — Source: Pliant Therapeutics
- 2026-04-30 12:30 EST — [Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-first-patient-dosed-in-fortify-the-phase-1b-indication-expansion-trial-evaluating-pln-101095-in-patients-with-ici-refractory-solid-tumors) — Source: Pliant Therapeutics
- 2026-04-18 17:31 EST — [Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-presentation-of-updated-data-from-the-phase-1-trial-of-pln-101095-in-patients-with-ici-refractory-solid-tumors-at-the-2026-aacr-annual-meeting) — Source: Pliant Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)